Craniopharyngioma
Craniopharyngioma is a tumor of the pituitary region (sellar/suprasellar) arising from epithelial remnants of the embryonic Rathke's pouch. Although histologically benign (WHO grade 1), it is clinically difficult to manage because of its proximity to vital structures such as the hypothalamus, optic chiasm and pituitary stalk. It shows two age peaks, in childhood and adulthood.
Përditësimi i fundit: 2026-06-07
Definition
Craniopharyngioma is a tumor that develops from the epithelial (ectodermal) remnants of Rathke's pouch, which forms the pituitary during embryonic development. It is classified as WHO grade 1 (benign) and does not metastasize; however, its clinical behavior is challenging because it can adhere to surrounding tissues and grow locally in an aggressive manner. There are two main histological subtypes: the adamantinomatous type (CTNNB1/beta-catenin mutation), mostly seen in children and containing calcification and cystic structure, and the papillary type (BRAF V600E mutation), seen almost exclusively in adults and predominantly solid.
Epidemiology
Craniopharyngioma accounts for a small fraction of all intracranial tumors but is one of the most common non-glial tumors of childhood. It has a bimodal age distribution, with peaks at roughly 5-14 years in childhood and 50-75 years in adulthood. The sex distribution is approximately equal. The adamantinomatous type predominates; the papillary type is rarer and confined to adults.
Symptoms
Symptoms arise from pressure on the pituitary, hypothalamus and visual pathways. Visual disturbances are common, particularly visual field loss from optic chiasm compression (bitemporal hemianopsia). Hormonal disturbances are prominent: growth failure and delayed puberty in children, fatigue and sexual dysfunction in adults, with diabetes insipidus, hypothyroidism and adrenal insufficiency potentially added. Headache, nausea-vomiting and hydrocephalus from raised intracranial pressure may occur, and in advanced cases appetite and weight dysregulation from hypothalamic involvement.
Diagnosis
Contrast-enhanced pituitary/sellar MRI is the gold standard. The adamantinomatous type typically shows a cystic component, a thick irregular wall and nodular enhancement; the papillary type is more solid with homogeneous enhancement. Computed tomography (CT) is valuable for demonstrating calcification, which is very common especially in the adamantinomatous type. In all patients, anterior and posterior pituitary function should be assessed comprehensively, and visual acuity and visual field testing performed. The differential diagnosis includes other sellar/suprasellar masses such as Rathke cleft cyst, pituitary adenoma, tuberculum sellae meningioma and germinoma.
Treatment Options
Surgery is the mainstay, and the extent of the approach is determined by the tumor's relationship to the hypothalamus. When the hypothalamus is not invaded, aggressive complete removal (gross total resection) may be pursued, whereas when the hypothalamus is invaded, a more limited removal followed by radiotherapy (subtotal resection plus radiotherapy) is preferred to avoid hypothalamic injury; in children a more conservative strategy is usually adopted to preserve quality of life. Surgical approaches include the endoscopic endonasal approach, now the modern standard, and transcranial approaches for lateral extension. Radiotherapy uses fractionated techniques and, especially in children, proton therapy, which better preserves neurocognitive function. As an important advance, BRAF/MEK inhibitors can produce striking responses in the papillary type harboring a BRAF V600E mutation. Intracystic treatments are an option for predominantly cystic cases.
Complications and Hypothalamic Dysfunction
In craniopharyngioma, the main long-term morbidity often arises not from the tumor itself but from its proximity to vital structures and from the treatment course. One of the most important problems is hypothalamic obesity: it results from damage to the hypothalamic centers regulating satiety and energy balance, is difficult to control and seriously affects quality of life. Neurocognitive impairment, multiple pituitary hormone deficiencies (panhypopituitarism) and diabetes insipidus are also common. Most of these patients need lifelong hormone replacement therapy and multidisciplinary follow-up.
Prognosis
Craniopharyngioma is a benign tumor with high overall survival rates; however, long-term quality of life may be affected by recurrence (at rates that vary with the extent of surgery) and by treatment-related permanent hormonal, visual and neurocognitive problems. In recurrent cases, repeat surgery, radiotherapy or, for the papillary type, targeted drugs are considered. Care is planned by a team including neurosurgery, endocrinology, radiation oncology, ophthalmology and other disciplines; outcomes vary from patient to patient and no outcome can be guaranteed.
Burimet
- Greenberg MS. Greenberg's Handbook of Neurosurgery. 10th ed. Thieme; 2023:849-860.
- Winn HR, ed. Youmans Neurological Surgery. 6th ed. Saunders; 2011:1515-1521.
- Osborn AG, Hedlund GL, Salzman KL. Osborn's Brain: Imaging, Pathology, and Anatomy. 2nd ed. Elsevier; 2018:802-803.
- Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System. Neuro Oncol. 2021.
Ky artikull ka karakter të përgjithshëm informues dhe nuk zëvendëson vizitën mjekësore. Vendimet për diagnozën dhe trajtimin janë individuale.